| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.81 [0.76, 0.87] | | < 1 | | 0% | 8 studies (8/-) | 100.0 % | some concern | not evaluable | moderate | crucial | - |
| deaths (OS) (extension) | 0.76 [0.53, 1.08] | | < 1 | | 0% | 1 study (1/-) | 93.7 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.72 [0.60, 0.86] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.73 [0.63, 0.84] | | < 1 | | 82% | 9 studies (9/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| DOR | 2.27 [1.44, 3.57] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| objective responses (ORR) | 1.43 [1.15, 1.78] | | > 1 | | 72% | 9 studies (9/-) | 99.9 % | some concern | not evaluable | moderate | non important | - |
| objective responses (ORR) (extension) | 1.68 [0.94, 3.01] | | > 1 | | 0% | 1 study (1/-) | 95.9 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.82 [0.47, 1.42] | | < 1 | | 44% | 6 studies (6/-) | 76.4 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 0.83 [0.52, 1.34] | | < 1 | | 92% | 6 studies (6/-) | 77.9 % | some concern | not evaluable | moderate | non important | - |
| AE leading to death (grade 5) | 1.15 [0.77, 1.73] | | < 1 | | 40% | 6 studies (6/-) | 24.5 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.82 [0.47, 1.43] | | < 1 | | 92% | 6 studies (6/-) | 75.9 % | some concern | not evaluable | moderate | non important | - |
| SAE (any grade) | 1.44 [1.08, 1.94] | | < 1 | | 72% | 5 studies (5/-) | 0.7 % | some concern | not evaluable | moderate | non important | - |
| SAE (grade 3-4) | 1.03 [0.80, 1.31] | | < 1 | | 0% | 1 study (1/-) | 42.1 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 1.38 [0.77, 2.47] | | < 1 | | 86% | 4 studies (4/-) | 14.2 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 0.61 [0.30, 1.23] | | < 1 | | 91% | 6 studies (6/-) | 91.6 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.58 [0.24, 1.38] | | < 1 | | 97% | 6 studies (6/-) | 89.2 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.17 [0.60, 2.25] | | < 1 | | 0% | 6 studies (6/-) | 32.5 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 0.07 [0.02, 0.29] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 1.32 [0.15, 11.35] | | < 1 | | 0% | 2 studies (2/-) | 40.0 % | some concern | not evaluable | moderate | non important | - |
| Alopecia TRAE (grade 3-4) | 0.79 [0.08, 7.60] | | < 1 | | 0% | 3 studies (3/-) | 58.1 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 1.27 [0.96, 1.68] | | < 1 | | 25% | 3 studies (3/-) | 5.0 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.78 [0.19, 3.17] | | < 1 | | 0% | 2 studies (2/-) | 63.7 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.74 [0.39, 1.40] | | < 1 | | 0% | 3 studies (3/-) | 82.1 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 3.39 [0.92, 12.50] | | < 1 | | 0% | 3 studies (3/-) | 3.3 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.77 [0.10, 5.99] | | < 1 | | 0% | 3 studies (3/-) | 59.7 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 1.96 [0.71, 5.43] | | < 1 | | 29% | 3 studies (3/-) | 9.8 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 3.12 [0.29, 33.74] | | < 1 | | 0% | 2 studies (2/-) | 17.7 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.65 [0.72, 3.78] | | < 1 | | 49% | 3 studies (3/-) | 11.9 % | some concern | not evaluable | moderate | non important | - |
| Dysgeusia TRAE (grade 3-4) | 0.49 [0.01, 24.77] | | < 1 | | 0% | 1 study (1/-) | 63.7 % | NA | not evaluable | | non important | - |
| Epistaxis TRAE (grade 3-4) | 8.09 [0.43, 153.59] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 1.27 [0.81, 1.99] | | < 1 | | 0% | 3 studies (3/-) | 15.1 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 1.78 [1.04, 3.05] | | < 1 | | 18% | 2 studies (2/-) | 1.7 % | some concern | not evaluable | moderate | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 5.48 [1.30, 23.18] | | < 1 | | 1% | 3 studies (3/-) | 1.1 % | some concern | not evaluable | moderate | non important | - |
| Hypertension TRAE (grade 3-4) | 1.00 [0.57, 1.78] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.62 [0.21, 12.58] | | < 1 | | 0% | 3 studies (3/-) | 32.3 % | some concern | not evaluable | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 2.01 [0.07, 60.02] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 2.18 [0.30, 15.78] | | < 1 | | 0% | 3 studies (3/-) | 22.1 % | some concern | not evaluable | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 4.04 [0.45, 36.32] | | < 1 | | 0% | 1 study (1/-) | 10.8 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 4.04 [0.45, 36.32] | | < 1 | | 0% | 1 study (1/-) | 10.8 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.96 [0.06, 15.37] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Leucopenia TRAE (grade 3-4) | 1.53 [0.83, 2.81] | | < 1 | | 0% | 2 studies (2/-) | 8.7 % | some concern | not evaluable | moderate | non important | - |
| Myalgia TRAE (grade 3-4) | 1.66 [0.21, 12.91] | | < 1 | | 0% | 2 studies (2/-) | 31.5 % | some concern | not evaluable | moderate | non important | - |
| Myositis TRAE (grade 3-4) | 1.49 [0.11, 19.42] | | < 1 | | 0% | 2 studies (2/-) | 38.2 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 2.00 [1.06, 3.77] | | < 1 | | 0% | 3 studies (3/-) | 1.6 % | some concern | not evaluable | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 1.49 [0.11, 19.42] | | < 1 | | 0% | 2 studies (2/-) | 38.2 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 1.12 [0.90, 1.39] | | < 1 | | 0% | 3 studies (3/-) | 15.1 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 2.93 [0.30, 28.98] | | < 1 | | 0% | 2 studies (2/-) | 18.0 % | some concern | not evaluable | moderate | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.50 [0.02, 14.97] | | < 1 | | 0% | 1 study (1/-) | 65.3 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 1.37 [0.62, 3.02] | | < 1 | | 0% | 2 studies (2/-) | 21.8 % | some concern | not evaluable | moderate | non important | - |
| Peripheral sensory neuropathy TRAE (grade 3-4) | 4.04 [0.45, 36.31] | | < 1 | | 0% | 1 study (1/-) | 10.8 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 2.31 [0.84, 6.37] | | < 1 | | 0% | 3 studies (3/-) | 5.3 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 2.28 [0.63, 8.28] | | < 1 | | 0% | 3 studies (3/-) | 10.6 % | some concern | not evaluable | moderate | non important | - |
| Sepsis TRAE (grade 3-4) | 2.01 [0.07, 60.02] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 4.04 [0.45, 36.32] | | < 1 | | 0% | 1 study (1/-) | 10.8 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 1.21 [0.85, 1.71] | | < 1 | | 0% | 3 studies (3/-) | 14.7 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 1.48 [0.65, 3.36] | | < 1 | | 0% | 3 studies (3/-) | 17.8 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| hepatitis (Autoimmune) AE (grade 3-4) | 0.98 [0.03, 29.35] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Abdominal pain AE (grade 3-4) | 1.23 [0.24, 6.38] | | < 1 | | 0% | 1 study (1/-) | 40.4 % | NA | not evaluable | | non important | - |
| Agranulocytosis (AE grade 3-4) | 0.24 [0.01, 7.31] | | < 1 | | 0% | 1 study (1/-) | 78.8 % | NA | not evaluable | | non important | - |
| Alopecia AE (grade 3-4) | 0.48 [0.04, 6.27] | | < 1 | | 0% | 2 studies (2/-) | 71.0 % | some concern | not evaluable | moderate | non important | - |
| Anaemia AE (grade 3-4) | 0.38 [0.08, 1.79] | | < 1 | | 95% | 3 studies (3/-) | 88.9 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia AE (grade 3-4) | 4.24 [0.72, 25.06] | | < 1 | | 0% | 2 studies (2/-) | 5.6 % | some concern | not evaluable | moderate | non important | - |
| Asthenia AE (grade 3-4) | 0.77 [0.34, 1.74] | | < 1 | | 36% | 3 studies (3/-) | 73.3 % | some concern | not evaluable | moderate | non important | - |
| Back pain AE (grade 3-4) | 2.09 [0.72, 6.04] | | < 1 | | 0% | 2 studies (2/-) | 8.7 % | some concern | not evaluable | moderate | non important | - |
| Blood creatinine increased AE (grade 3-4) | 1.97 [0.09, 43.77] | | < 1 | | 0% | 1 study (1/-) | 33.7 % | NA | not evaluable | | non important | - |
| Colitis AE (grade 3-4) | 2.96 [0.15, 59.25] | | < 1 | | 0% | 1 study (1/-) | 24.2 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 1.95 [0.54, 7.07] | | < 1 | | 0% | 3 studies (3/-) | 15.6 % | some concern | not evaluable | moderate | non important | - |
| Cough AE (grade 3-4) | 2.15 [0.42, 11.13] | | < 1 | | 0% | 3 studies (3/-) | 18.1 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite AE (grade 3-4) | 0.68 [0.18, 2.61] | | < 1 | | 48% | 3 studies (3/-) | 71.5 % | some concern | not evaluable | moderate | non important | - |
| Diabetes mellitus AE (grade 3-4) | 1.97 [0.09, 43.77] | | < 1 | | 0% | 1 study (1/-) | 33.7 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 0.62 [0.31, 1.23] | | < 1 | | 15% | 3 studies (3/-) | 91.5 % | some concern | not evaluable | moderate | non important | - |
| Dizziness AE (grade 3-4) | 0.49 [0.03, 7.86] | | < 1 | | 0% | 1 study (1/-) | 69.1 % | NA | not evaluable | | non important | - |
| Dry skin AE (grade 3-4) | 0.24 [0.01, 7.31] | | < 1 | | 0% | 1 study (1/-) | 78.8 % | NA | not evaluable | | non important | - |
| Dysgeusia AE (grade 3-4) | 0.68 [0.04, 10.92] | | < 1 | | 0% | 2 studies (2/-) | 60.6 % | some concern | not evaluable | moderate | non important | - |
| Dyspnoea AE (grade 3-4) | 2.20 [0.60, 8.13] | | < 1 | | 56% | 3 studies (3/-) | 11.9 % | some concern | not evaluable | moderate | non important | - |
| Epistaxis AE (grade 3-4) | 0.49 [0.03, 7.86] | | < 1 | | 0% | 1 study (1/-) | 69.1 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.81 [0.43, 1.54] | | < 1 | | 44% | 3 studies (3/-) | 73.8 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia AE (grade 3-4) | 0.10 [0.00, 1.89] | | < 1 | | 87% | 3 studies (3/-) | 93.6 % | some concern | not evaluable | moderate | non important | - |
| Gastritis AE (grade 3-4) | 1.97 [0.09, 43.77] | | < 1 | | 0% | 1 study (1/-) | 33.7 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 0.98 [0.03, 29.35] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Hypertension AE (grade 3-4) | 1.00 [0.30, 3.31] | | < 1 | | 0% | 2 studies (2/-) | 50.2 % | some concern | not evaluable | moderate | non important | - |
| Hyperthyroidism AE (grade 3-4) | 0.49 [0.03, 7.86] | | < 1 | | 0% | 1 study (1/-) | 69.1 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 1.97 [0.09, 43.77] | | < 1 | | 0% | 1 study (1/-) | 33.7 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 1.71 [0.40, 7.37] | | < 1 | | 29% | 2 studies (2/-) | 23.7 % | some concern | not evaluable | moderate | non important | - |
| Increased ALT AE (grade 3-4) | 1.49 [0.26, 8.74] | | < 1 | | 52% | 2 studies (2/-) | 32.8 % | some concern | not evaluable | moderate | non important | - |
| Infusion-related reaction AE (grade 3-4) | 0.98 [0.03, 29.35] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Leucopenia AE (grade 3-4) | 0.79 [0.13, 4.82] | | < 1 | | 61% | 2 studies (2/-) | 60.2 % | some concern | not evaluable | moderate | non important | - |
| Myalgia AE (grade 3-4) | 0.36 [0.06, 2.27] | | < 1 | | 0% | 2 studies (2/-) | 86.1 % | some concern | not evaluable | moderate | non important | - |
| Nausea AE (grade 3-4) | 1.04 [0.32, 3.45] | | < 1 | | 43% | 3 studies (3/-) | 47.1 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia AE (grade 3-4) | 0.12 [0.01, 2.04] | | < 1 | | 96% | 3 studies (3/-) | 92.7 % | some concern | not evaluable | moderate | non important | - |
| Pancytopenia (AE grade 3-4) | 0.48 [0.10, 2.18] | | < 1 | | 0% | 2 studies (2/-) | 83.0 % | some concern | not evaluable | moderate | non important | - |
| Paraesthesia AE (grade 3-4) | 1.97 [0.09, 43.77] | | < 1 | | 0% | 1 study (1/-) | 33.7 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy AE (grade 3-4) | 0.29 [0.03, 2.86] | | < 1 | | 48% | 2 studies (2/-) | 85.3 % | some concern | not evaluable | moderate | non important | - |
| Peripheral oedema AE (grade 3-4) | 0.53 [0.13, 2.16] | | < 1 | | 0% | 2 studies (2/-) | 81.1 % | some concern | not evaluable | moderate | non important | - |
| Peripheral sensory neuropathy AE (grade 3-4) | 0.98 [0.24, 3.96] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Pneumonia AE (grade 3-4) | 1.09 [0.57, 2.07] | | < 1 | | 12% | 2 studies (2/-) | 40.1 % | some concern | not evaluable | moderate | non important | - |
| Pneumonitis AE (grade 3-4) | 0.24 [0.01, 7.31] | | < 1 | | 0% | 1 study (1/-) | 78.8 % | NA | not evaluable | | non important | - |
